Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer

Mu Yi Hua; Hung Wei Yang; Cheng Keng Chuang; Rung Ywan Tsai; Wen Jauh Chen; Kun Lung Chuang; Ying Hsu Chang; Heng Chang Chuang; See Tong Pang

doi:10.1016/j.biomaterials.2010.05.061

Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer

Mu Yi Hua, Hung Wei Yang, Cheng Keng Chuang, Rung Ywan Tsai, Wen Jauh Chen, Kun Lung Chuang, Ying Hsu Chang, Heng Chang Chuang, See Tong Pang^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

126 Scopus citations

Abstract

A nontoxic drug nanocarrier containing carboxyl groups was successfully developed by mixing magnetic nanoparticles (MNPs) of Fe₃O₄ with the water-soluble polyaniline derivative poly[aniline-co-sodium N-(1-one-butyric acid) aniline] (SPAnNa) and doping with HCl aqueous solution to form SPAnH/MNPs shell/core. SPAnH/MNPs could be used to effectively immobilize the hydrophobic drug paclitaxel (PTX), thus enhancing the drug's thermal stability and water solubility. Up to 302.75 μg of PTX could be immobilized per mg of SPAnH/MNPs. SPAnH/MNPs-bound-PTX (bound-PTX) was more stable than free-PTX at both 25 °C and 37 °C. Furthermore, bound-PTX was more cytotoxic to human prostate carcinoma cells (PC3 and CWR22R) than free-PTX at 37 °C, and the inhibition of cellular growth was even more pronounced when magnetic targeting was applied to the bound-PTX. These data indicate that this magnetically targeted drug delivery system provides more effective treatment of prostate cancer cells using lower therapeutic doses and thus with potentially fewer side-effects.

Original language	English
Pages (from-to)	7355-7363
Number of pages	9
Journal	Biomaterials
Volume	31
Issue number	28
DOIs	https://doi.org/10.1016/j.biomaterials.2010.05.061
State	Published - 10 2010

Keywords

Drug nanocarriers
Paclitaxel
Polyaniline derivative
Prostate cancer
Taxane drug

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.biomaterials.2010.05.061

Cite this

@article{68e4bf83e9474783804f5ecade27c1c1,

title = "Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer",

abstract = "A nontoxic drug nanocarrier containing carboxyl groups was successfully developed by mixing magnetic nanoparticles (MNPs) of Fe3O4 with the water-soluble polyaniline derivative poly[aniline-co-sodium N-(1-one-butyric acid) aniline] (SPAnNa) and doping with HCl aqueous solution to form SPAnH/MNPs shell/core. SPAnH/MNPs could be used to effectively immobilize the hydrophobic drug paclitaxel (PTX), thus enhancing the drug's thermal stability and water solubility. Up to 302.75 μg of PTX could be immobilized per mg of SPAnH/MNPs. SPAnH/MNPs-bound-PTX (bound-PTX) was more stable than free-PTX at both 25 °C and 37 °C. Furthermore, bound-PTX was more cytotoxic to human prostate carcinoma cells (PC3 and CWR22R) than free-PTX at 37 °C, and the inhibition of cellular growth was even more pronounced when magnetic targeting was applied to the bound-PTX. These data indicate that this magnetically targeted drug delivery system provides more effective treatment of prostate cancer cells using lower therapeutic doses and thus with potentially fewer side-effects.",

keywords = "Drug nanocarriers, Paclitaxel, Polyaniline derivative, Prostate cancer, Taxane drug",

author = "Hua, {Mu Yi} and Yang, {Hung Wei} and Chuang, {Cheng Keng} and Tsai, {Rung Ywan} and Chen, {Wen Jauh} and Chuang, {Kun Lung} and Chang, {Ying Hsu} and Chuang, {Heng Chang} and Pang, {See Tong}",

year = "2010",

month = oct,

doi = "10.1016/j.biomaterials.2010.05.061",

language = "英语",

volume = "31",

pages = "7355--7363",

journal = "Biomaterials",

issn = "0142-9612",

publisher = "Elsevier Ltd",

number = "28",

}

TY - JOUR

T1 - Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer

AU - Hua, Mu Yi

AU - Yang, Hung Wei

AU - Chuang, Cheng Keng

AU - Tsai, Rung Ywan

AU - Chen, Wen Jauh

AU - Chuang, Kun Lung

AU - Chang, Ying Hsu

AU - Chuang, Heng Chang

AU - Pang, See Tong

PY - 2010/10

Y1 - 2010/10

N2 - A nontoxic drug nanocarrier containing carboxyl groups was successfully developed by mixing magnetic nanoparticles (MNPs) of Fe3O4 with the water-soluble polyaniline derivative poly[aniline-co-sodium N-(1-one-butyric acid) aniline] (SPAnNa) and doping with HCl aqueous solution to form SPAnH/MNPs shell/core. SPAnH/MNPs could be used to effectively immobilize the hydrophobic drug paclitaxel (PTX), thus enhancing the drug's thermal stability and water solubility. Up to 302.75 μg of PTX could be immobilized per mg of SPAnH/MNPs. SPAnH/MNPs-bound-PTX (bound-PTX) was more stable than free-PTX at both 25 °C and 37 °C. Furthermore, bound-PTX was more cytotoxic to human prostate carcinoma cells (PC3 and CWR22R) than free-PTX at 37 °C, and the inhibition of cellular growth was even more pronounced when magnetic targeting was applied to the bound-PTX. These data indicate that this magnetically targeted drug delivery system provides more effective treatment of prostate cancer cells using lower therapeutic doses and thus with potentially fewer side-effects.

AB - A nontoxic drug nanocarrier containing carboxyl groups was successfully developed by mixing magnetic nanoparticles (MNPs) of Fe3O4 with the water-soluble polyaniline derivative poly[aniline-co-sodium N-(1-one-butyric acid) aniline] (SPAnNa) and doping with HCl aqueous solution to form SPAnH/MNPs shell/core. SPAnH/MNPs could be used to effectively immobilize the hydrophobic drug paclitaxel (PTX), thus enhancing the drug's thermal stability and water solubility. Up to 302.75 μg of PTX could be immobilized per mg of SPAnH/MNPs. SPAnH/MNPs-bound-PTX (bound-PTX) was more stable than free-PTX at both 25 °C and 37 °C. Furthermore, bound-PTX was more cytotoxic to human prostate carcinoma cells (PC3 and CWR22R) than free-PTX at 37 °C, and the inhibition of cellular growth was even more pronounced when magnetic targeting was applied to the bound-PTX. These data indicate that this magnetically targeted drug delivery system provides more effective treatment of prostate cancer cells using lower therapeutic doses and thus with potentially fewer side-effects.

KW - Drug nanocarriers

KW - Paclitaxel

KW - Polyaniline derivative

KW - Prostate cancer

KW - Taxane drug

UR - http://www.scopus.com/inward/record.url?scp=77955269725&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2010.05.061

DO - 10.1016/j.biomaterials.2010.05.061

M3 - 文章

C2 - 20609471

AN - SCOPUS:77955269725

SN - 0142-9612

VL - 31

SP - 7355

EP - 7363

JO - Biomaterials

JF - Biomaterials

IS - 28

ER -

Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this